Moffitt Research On Myelodysplastic Syndromes Appears In New England Journal Of Medicine
H. Lee Moffitt Cancer Center & Research Institute announced publication of the final results from a pivotal Phase II trial of Revlimid in patients with an incurable blood cancer know as myelodysplastic syndromes (MDS) in the October 5 issue of the New England Journal of Medicine. [click link for full article]
posted by Smile Community @ 7:08 AM
0 Comments:
Post a Comment
<< Home